UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Main results already published
Unique ID issued by UMIN UMIN000004211
Receipt No. R000005059
Scientific Title A phase II study of Cord blood transplantation for elderly patients with hematologic malignancies using fludarabine and intravenous busulfan.
Date of disclosure of the study information 2010/09/15
Last modified on 2018/03/21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title A phase II study of Cord blood transplantation for elderly patients with hematologic malignancies using fludarabine and intravenous busulfan.
Acronym JSCT-FB10 CB
Scientific Title A phase II study of Cord blood transplantation for elderly patients with hematologic malignancies using fludarabine and intravenous busulfan.
Scientific Title:Acronym JSCT-FB10 CB

Condition AML,MDS
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Narrative objectives1 To investigate efficacy of Cord blood transplantation using 180mg/m2 of fludarabine and 12.8mg/kg of intravenous busulfan for elderly patients aged 55-70 with AML or MDS.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Primary outcomes Event-free survival at 1 year after transplantation
Key secondary outcomes

Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Dynamic allocation
Institution consideration

No. of arms 1
Purpose of intervention Treatment
Type of intervention
Interventions/Control_1 Conditioning regimen:
Flu 180mg/m2 + ivBu 12.8mg/kg + TBI 2Gy X 2

GVHD prophylaxis:
tacrolimus + oral mycophenolate mofetil (MMF)(30mg/kg/day in two divided doses, from day 0 to 30, and subsequently tapered and discontinued within 2 weeks,provided that there is no active GVHD requiring treatment)

Age-lower limit
55 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria 1.Patients diagnosed as AML or MDS who meet the following conditions,
(a)Patients with AML(except M3)who are in advanced stage beyond first complete remission, are in high risk disease category according to SWOG/ECOG criteria, received more than one course of chemotherapy to achieve complete remission, AML/MLD in first remission, or AML with prior history of myelodysplastic syndrome
(B)Patients with MDS who are in poor prognosis group with high or very high score according to WHO classification-based prognostic scoring system, or required platelet transfusions of at least 10 units/week or red cell transfusions of at least 2 units/month.
3.HLA matched or less than 3 antigen-mismatched CB with more than 2 X 10^7/kg nucleated cells.
4.ECOG PS:0-2
5.Those who have no severe organ dysfunction (T. Bil<2.0mg/dL, AST<=3 X upper limit of normal,ALT<=3 X upper limit of normal, Cr<2.0mg/dl, EF>50%, SpO2>95%)
6.Those who give written informed consent following sufficient explanation.
7.Those who are evaluated to be able to survive more than 3 months.
Key exclusion criteria 1.Those who are positive for anti-HIV antibody
2.Those who have history of gemtuzumab ozogamicin (MylotargTM) use within 4 months
3.Those who have coinciding active malignancies
4.Those who have uncontrolled psychiatric disorder
5.Those who have active infection
6.Those who have prior hematopoietic stem cell transplantation
7.Those who have history of chemotherapy within 30 days before transplant (except hydroxycarbamide or cytarabine therapy for blast control)
8.Those who have hypersensitivity to drugs included in this protocol therapy
9.Those who are considered as inappropriate to register by attending physicians.
Target sample size 42

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Naoya Uchida
Organization Toranomon Hospital, Tokyo, Japan
Division name Department of Hematology
Zip code
Address 2-2-2,Toranomonn,Minato-ku,Tokyo,Japan

Public contact
Name of contact person
1st name
Middle name
Last name
Organization JSCT
Division name FB10 datacenter
Zip code
Homepage URL

Institute Japan Study Group for Cell Therapy and Transplantation

Funding Source
Organization Resarch Foundation for Community Medicine
Category of Funding Organization Non profit foundation
Nationality of Funding Organization

Other related organizations
Name of secondary funder(s)

IRB Contact (For public release)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2


Other administrative information
Date of disclosure of the study information
2010 Year 09 Month 15 Day

Related information
URL releasing protocol
Publication of results Published

URL related to results and publications
Number of participants that the trial has enrolled
142 elderly patients (88 men and 54 women; median age, 61 years; range, 55-70 years) were participated, 103 AML and 39 MDS.  21 received related bone marrow (BM) or peripheral blood (PB), 50 did unrelated BM, and 71 did cord blood (CB).  105 (74%) experienced grade III or greater toxicities including 4 SOS.  Neutrophil engraftment was achieved in 70 out of 71 related BM/PB or unrelated BM recipients, and 61 of 71 UCB recipients.  Cumulative incidences of relapse and non-relapse mortality after 2 years were 24 % and 24.1%, respectively.  Overall and event-free survivals at 2 years were 53.3% and 47.4 %, respectively.  2-year OS was 61.5% in related BM/PB, 67.8% in UBM, and 40.8% in CB recipients, showing inferior OS in CB recipients to the other donor types (P<0.05).  However, for those in good performance status (ECOG 0) and had low blast count in BM (<5%), the differences became not significant (2-year OS were 77.3% in related BM/PB, 68.4% in UBM, and 65.0% in CB recipients). 
Conclusion: The myeloablative dose of ivBu was well tolerated without increased toxicity-related mortality.  The differences between CB and the others could likely be due to relatively poor conditions of CB recipients.  This trial was registered as #UMIN000002426, #UMIN000004213, and #UMIN000004211. 
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Main results already published
Date of protocol fixation
2010 Year 09 Month 01 Day
Date of IRB
Anticipated trial start date
2010 Year 09 Month 10 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
2017 Year 08 Month 27 Day

Other related information

Management information
Registered date
2010 Year 09 Month 15 Day
Last modified on
2018 Year 03 Month 21 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.